Borealis Ventures
VC Fund
Hanover, United States
Borealis Ventures is a VC fund in Hanover focused on Software and Health Care. companies in such fields as 3D design, construction management, and data-driven software.
- Total investments:
- 58
- Last investment:
- Lead investor:
- 21%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Borealis Ventures invests in
SoftwareHealth CareBiotechnologyConstructionEnterprise Software
Stages Borealis Ventures invests in
Series ASeries BSeries CSeedFunding Round
Countries Borealis Ventures invests in
United StatesUnited KingdomSwitzerland
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ben Shaw
|
|||
Emily Snyder
|
|||
Jesse Devitte
|
|||
Julia Stephanus
|
|||
Matt Harris
|
Investment Focus
Industry
- Software 11 (19%)
- Health Care 10 (17%)
- Biotechnology 7 (12%)
- Construction 5 (9%)
- Enterprise Software 5 (9%)
Stage
- Series A 18 (31%)
- Series B 10 (17%)
- Series C 7 (12%)
- Seed 5 (9%)
- Funding Round 5 (9%)
Country
- United States 31 (53%)
- United Kingdom 2 (3%)
- Switzerland 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ben Shaw
Partner
|
Partner | Total investments: 0 | Find email | |
|
Emily Snyder
Principal
|
Principal | Total investments: 0 | Find email | |
|
Jesse Devitte
Co-Founder
|
Co-Founder | Total investments: 21 | Find email | |
|
Julia Stephanus
Partner
|
Partner | Total investments: 0 | Find email | |
|
Matt Harris
Co-Founder & Managing General Partner
|
Co-Founder & Managing General Partner | Total investments: 92 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ASTRA Therapeutics
|
ASTRA Therapeutics is a medication development business that uses cutting-edge science and technology to discover new therapeutic treatment candidates for the full spectrum of parasite disorders. | $9.7M / Seed / Jul 24, 2025 | |
Ankyra
|
Ankyra is developing a platform to significantly improve both the safety and efficacy of cytokine immunotherapies for cancer. | $45M / Series B / Nov 12, 2021 | |
Orbit Discovery
|
Orbit Discovery is a peptide display company identifying potential peptide drugs for a range of chronic diseases. Peptides offer the potential to make drugs with the specificity and efficacy of large biologic molecules combined with the smaller dose size, simpler routes of delivery and lower cost of manufacturing found with small molecules. Theyare, therefore, uniquely suited to the treatment of chronic diseases which impact large patient populations. Their technology supports all of the improvements that can be made to peptides which make them better drugs whilst simplifying the discovery process and accelerating drug development | $7.3M / Jul 20, 2021 | |
|
Orbit Discovery
|
Orbit Discovery is a peptide display company identifying potential peptide drugs for a range of chronic diseases. Peptides offer the potential to make drugs with the specificity and efficacy of large biologic molecules combined with the smaller dose size, simpler routes of delivery and lower cost of manufacturing found with small molecules. Theyare, therefore, uniquely suited to the treatment of chronic diseases which impact large patient populations. Their technology supports all of the improvements that can be made to peptides which make them better drugs whilst simplifying the discovery process and accelerating drug development | $7.6M / Seed / Jul 20, 2021 | |
Evox Therapeutics
|
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading Life Sciences Venture Capital groups and supported by a comprehensive intellectualproperty portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families.Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies. Evox is leading the development within this emerging therapeutic space. | $96.7M / Series C / Feb 18, 2021 | |
Ovation
|
Ovation provides data and operations solutions to researchers, scientists, and labs throughout the life sciences industry. Our offering for researchers includes cloud-based storage for data related to experiments and analyses that enables easy collaborations within and between labs, and technology that allows researchers to describe and visualizethe relationships between their data. Their offering for service labs in the precision medicine space is a first-of-its-kind solution that merges training records, document management, and sample tracking in an easy, cloud-based application.It was established in 2009 and is based in Cambridge, Massachusetts. | $21.5M / Series B / Dec 16, 2020 | |
FidoCure
|
FidoCure is transforming canine cancer care through AI-driven precision medicine. By harnessing data from naturally occurring canine cancers via next-generation sequencing and clinical information, FidoCure has developed the world's largest proprietary learning database for canine cancer. FidoCure is pioneering first-in-class care for caninecancer, which represents the largest unmet need for pet dogs. By connecting human and veterinary oncology, FidoCure enhances comparative oncology, improves outcomes across species, and creates new opportunities for drug development that benefit both pets and humans. | $10M / Series A / Oct 29, 2020 | |
Compass Therapeutics
|
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeuticsthat can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. | $60.5M / Venture - Series Unknown / Jun 23, 2020 | |
|
Compass Therapeutics
|
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeuticsthat can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. | $60.5M / Venture - Series Unknown / Jun 23, 2020 | |
|
Ovation
|
Ovation provides data and operations solutions to researchers, scientists, and labs throughout the life sciences industry. Our offering for researchers includes cloud-based storage for data related to experiments and analyses that enables easy collaborations within and between labs, and technology that allows researchers to describe and visualizethe relationships between their data. Their offering for service labs in the precision medicine space is a first-of-its-kind solution that merges training records, document management, and sample tracking in an easy, cloud-based application.It was established in 2009 and is based in Cambridge, Massachusetts. | $5M / Series A / Mar 14, 2019 | |
| See all 58 investments → | |||
Co-Investors
OrbiMed
10 deals together
Google Ventures
9 deals together
Kodiak Venture Partners
8 deals together
Village Ventures
6 deals together
Cowen Healthcare Investments
5 deals together
Egan-Managed Capital
5 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Enterprise Investors
77,348 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Proptech Investors
20,668 investors
Biotechnology Investors
19,370 investors
Enterprise Software Investors
13,836 investors
Construction Investors
6,359 investors
FAQ
What does Borealis Ventures invest in?
Borealis Ventures invests primarily in Software, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 58 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Borealis Ventures?
Public channels for Borealis Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Borealis Ventures?
The team at Borealis Ventures includes Ben Shaw (Partner), Emily Snyder (Principal) and Jesse Devitte (Co-Founder), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
